Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Cepetor** is a veterinary brand name for medetomidine hydrochloride, a potent synthetic α2-adrenergic receptor agonist formulated as a 1 mg/ml solution for injection primarily for dogs, and also cats. It provides reliable sedation and analgesia, making it suitable for clinical examinations, minor procedures, premedication for general anesthesia, and facilitating handling. Developed originally by Orion Pharma, it is marketed by companies including Modern Veterinary Therapeutics (Canada/US), CP Pharma, and historically Bioniche Life Sciences for distribution in regions like Australia. Effects are reversible with atipamezole (e.g., Revertor). Dosing typically ranges from 10-40 µg/kg IV/IM for premedication, with effects metabolized hepatically.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Cepetor.